Noah Getz

Noah Getz

Auto-generated profile, based on publicly available information

Noah Getz

Boltz PBC

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
NGNoah Getz
Noah Getz
GSGeoffrey Smith
Geoffrey Smith
ACAvene Colgan
Avene Colgan
VFVincent Fan
Vincent Fan
LCLuca Cavalleri
Luca Cavalleri
SPSaro Passaro
Saro Passaro
We present BoltzMol-1, a small-molecule hit discovery pipeline, centered on an optimized version of Boltz-2, explicitly adapted for prospective discovery. Reliable hit discovery that generalizes across target classes (rather than only the well-characterized families that dominate existing ligand data) would broaden the range of biology accessible to small-molecule intervention and reduce reliance on resource-intensive high-throughput screening. Towards this goal, the system prioritizes compounds for rapid experimental validation by coupling model-driven ranking with streamlined procurement from commercial catalogs. To improve developability at the point of selection, we introduce a suite of ADMET models for kinetic solubility (logS), lipophilicity (logD), and Caco-2 permeability. These models act as an early triage layer, systematically filtering out compounds with unfavorable physicochemical and absorption properties prior to synthesis or purchase. Across a panel of ten targets (most with no representation in the underlying affinity training data) we observe strong prospective performance on challenging systems. Functional actives or binders were identified for 6 of 10 targets, despite modest experimental budgets of 28-96 compounds per target. These results include successes on receptors and enzymes traditionally considered difficult for structure- or ligand-based approaches. Collectively, this work establishes a practical framework for low-throughput, cost-constrained discovery campaigns capable of delivering chemically tractable binders with favorable property profiles. Figure 1: Overview of the prospective virtual-screening campaigns across all targets. For each target, the panel shows the predicted protein-ligand complex together with the number of compounds tested, the number of confirmed actives/binders, and the assays used for screening and follow-up.